What do systematic reviews say?

Metformin vs dipeptidyl‐peptidase 4 inhibitors

The review found no eligible studies for this question.

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin vs glucagon like peptide‐1 analogues

The review found no eligible studies for this question.

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin vs meglitinides

The review found no eligible studies for this question.

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐CD52 mAb maintenance therapy vs observation

The review found no eligible studies for this question.

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

The review found no eligible studies for this question.

• Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Immunomodulatory drug maintenance therapy vs placebo/observation

The review found no eligible studies for this question.

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

The review found no eligible studies for this question.

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: pioglitazone monotherapy vs placebo

The review found no eligible studies for this question.

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: pioglitazone monotherapy vs no intervention

The review found no eligible studies for this question.

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Animal‐assisted therapy (AAT (live animal)) vs no AAT

• Animal‐assisted therapy for dementia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Moderate

Manual therapy, prescribed exercises or both vs no intervention or minimal intervention

• Manual therapy and exercise for lateral elbow pain 2024 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 113 participants
  Low

Animal‐assisted therapy (AAT (live animal)) vs robotic animals

• Animal‐assisted therapy for dementia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 78 participants
  Low

Metformin vs insulin

• Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 208 participants
  Very low

Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Immune checkpoint inhibitors vs any first‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 393 participants
  Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 727 participants
  Low